01/05/2019 20:00:00

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Interface, Inc. (TILE)

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Interface, Inc. (“Interface” or the “Company”) (NASDAQ: TILE). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/tile.

The investigation concerns whether Interface and certain of its officers and/or directors have violated federal securities laws.

On April 24, 2019, Interface announced receipt of a letter in November 2017 from the U.S. Securities and Exchange Commission (“SEC”) requesting that the Company voluntarily provide information and documents in connection with an investigation into the Company's historical quarterly earnings per share calculations and rounding practices during the period 2014-2017.  Interface also reported receipt of subpoenas from the SEC in February 2018, July 2018 and April 2019 requesting additional documents and information.  In the fourth quarter of 2018, at the SEC’s request, Interface conducted an internal investigation into these and other related issues for seven quarters in 2015, 2016 and 2017.  Interface also announced that its Vice President and Chief Accounting Officer was placed on paid administrative leave from Interface after the Company learned that in 2018, in the process of collecting materials from 2015, 2016 and 2017 for production to the SEC, he added certain notes to those materials that were then produced to the SEC.  Following this news, Interface’s stock price fell $1.43 per share, or 8.37%, to close at $15.66 per share on April 25, 2019.

If you are aware of any facts relating to this investigation, or purchased Interface shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/tile. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

BGG Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 May
OMXC25
Et stort flertal af klimaforskerne mener klimaændringerne er menneskeskabte. Dvs. de uddannede perso..
28
15 May
DANSKE
Meget interessant refleksion skrevet af Maui. Det kan vores medier godt lære lidt af. Det der kommer..
25
15 May
PNDORA
I gaar aftes sad jeg og kiggede lidt naermere paa guidance fra Pandora for FY2019, som de meldte ud ..
22
14 May
E:THIN
Så sidder jeg her og glor på mit depot. Thinfilm falder ekstra meget i øjnene med afkast på minus 96..
20
17 May
VELO
Hej Alle,   Har siddet og kigget på regnskabet, for at finde ud af hvordan 2019 ender. Umiddelbart e..
18
18 May
VWS
Ditlev.. Havde store ambitioner, og store armbevægelser .. Ikke alt gik godt.. Men finanskrisen kan..
17
18 May
OMXC25
Når man begynder at bruge børn som Greta Thunberg for at fremhæve et budskab ringer advarselsklokker..
17
15 May
DANSKE
Apropos skribent 6212.. Og Danske Bank..Ja så må man lade vedkommende at han/hun fik ret. Han anbefa..
16
14 May
DANSKE
Sjovt at der ikke er nogen kritik af SKATs manglende kontrolindsats i forbindelse med momssvindlen, ..
16
18 May
ZEAL
Nedenfor er det samlet udskift af Q1 telefonkonferencen for Zealand Pharma.    Jeg har først trukket..
15

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
2
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
3
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 3rd quarter and 9 months of 2018/2019 financial year
4
Eimskip: Letter from Gylfi Sigfússon´s attorney concerning District Prosecutor‘s investigation
5
Trilogy International Partners Inc. Announces New Zealand CEO Transition

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 May 2019 12:20:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB1 - 2019-05-20 13:20:24 - 2019-05-20 12:20:24 - 1000 - Website: OKAY